Abe Y, Nakamura M, Saegusa R, Ueyama Y, Ogata T, Tamaoki N
Department of Pathology, Tokai University School of Medicine, Kanagawa Academy of Science and Technology, Japan.
Tokai J Exp Clin Med. 1993 Dec;18(3-6):99-106.
We studied the correlation between in vivo responsiveness of KB xenografts to anticancer drugs and the expression level of the human multidrug resistance gene (MDR1) encoding P-Glycoprotein (P-Gp). We established KB xenografts (xeKB3-1 and xeKB8-5) by inoculating these in vitro lines into nude mice. The responsiveness was evaluated by an in vivo chemosensitivity assay (T/C; sensitive, < 50%). Xenograft xeKB3-1 was sensitive to vincristine (VCR) (T/C, 48%), and xeKB8-5 was resistant to VCR (T/C, 72%). We selected a VCR-resistant variant (xeKB3-1-R, T/C, 76%) by treating xeKB3-1 with VCR (1.2 mg/kg, x3) in vivo. The MDR1 expression was evaluated by a semi-quantitative assay using reverse transcription-polymerase chain reaction. A MDR1 expression pattern in xeKB3-1 and xeKB8-5 in vivo was the same as that to KB3-1 and KB8-5 in vitro. The xenograft xeKB3-1-R expressed definitive but significantly lower levels of MDR1 than xeKB8-5. These results suggest that acquired drug resistance is related to minimally enhanced expression of the P-Gp protein/MDR1 gene in KB xenografts in vivo.
我们研究了KB异种移植瘤对抗癌药物的体内反应性与编码P-糖蛋白(P-Gp)的人类多药耐药基因(MDR1)表达水平之间的相关性。我们通过将这些体外细胞系接种到裸鼠体内建立了KB异种移植瘤(xeKB3-1和xeKB8-5)。通过体内化学敏感性试验(T/C;敏感,<50%)评估反应性。异种移植瘤xeKB3-1对长春新碱(VCR)敏感(T/C,48%),而xeKB8-5对VCR耐药(T/C,72%)。我们通过在体内用VCR(1.2mg/kg,x3)处理xeKB3-1筛选出了一个VCR耐药变体(xeKB3-1-R,T/C,76%)。使用逆转录-聚合酶链反应通过半定量试验评估MDR1表达。xeKB3-1和xeKB8-5在体内的MDR1表达模式与KB3-1和KB8-5在体外的相同。异种移植瘤xeKB3-1-R表达的MDR1水平明确但明显低于xeKB8-5。这些结果表明,获得性耐药与体内KB异种移植瘤中P-Gp蛋白/MDR1基因的最小增强表达有关。